drugset
drugset / Trial / NCT06891040

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

NCT06891040 ↗

Phase 2 Completed 118 enrolled Jiangsu vcare pharmaceutical technology co., LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, vehicle controlled phase II clinical study

Timeline

Start
2025-04-28
Primary completion
2025-10-31
Completion
2025-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VC005 Unknown — Topical

Indications

atopic eczema